The mutations (MTOR, ACVR1B, GNAQ, ATM, CNOT1, EP300, ARID2, RET and MAP2K4) newly detected in HGCAs in the present study have been reported in CRCs at low incidences (0.9%-8.9%) as well as other cancers [31–33]. This evidence concerns the gene ARID2 and cancer.